Preclinical studies suggested that dysregulation of the stemness-related FGFR2 signaling pathway plays a key role in the oncogenic processes of the immune-desert UPS and FGFR2 pharmacological inhibition impaired the tumor growth of patient derived xenograft. The gene discussed is FGFR2; the disease is neoplasm.